Efficacy and Limitations of Oral Inotropic Agents for the Treatment of Chronic Heart Failure
| العنوان: | Efficacy and Limitations of Oral Inotropic Agents for the Treatment of Chronic Heart Failure |
|---|---|
| المؤلفون: | Yoshihiko Seino, Takayoshi Ohba, Kenji Yodogawa, Daisuke Murakami, Toru Inami, Nakahisa Kimata, Kyoichi Mizuno, Mitsunori Maruyama, Junko Abe, Masamichi Takano, Chikao Ibuki, Koji Murai |
| المصدر: | International Heart Journal. 54:75-81 |
| بيانات النشر: | International Heart Journal (Japanese Heart Journal), 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Inotrope, medicine.medical_specialty, medicine.drug_class, business.industry, Denopamine, Retrospective cohort study, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Pimobendan, Concomitant, Internal medicine, Heart failure, medicine, Natriuretic peptide, Cardiology, Cardiology and Cardiovascular Medicine, business, Beta blocker, medicine.drug |
| الوصف: | The heart failure guideline in Japan has stated the necessity of investigating the role of oral inotropic agents in patients with chronic heart failure (CHF), which are clinically available only in Japan. A total of 1,846 consecutive patients with heart failure (mean: 69.5 years old, 1,279 males) treated at our institute from November 2009 to August 2010 were investigated retrospectively. Thirty-one patients (1.84%) who had taken oral inotropic agents (pimobendan 27, docarpamine 6, and denopamine 4) were extracted for this study, and the efficacy and limitations of the treatments were analyzed. Following the oral inotropic treatment, the NYHA functional class (P = 0.017), cardiothoracic ratio (P = 0.002) and B-type natriuretic peptide levels (P = 0.011) were significantly improved, and the number of emergency room (ER) visits (P < 0.001) and hospitalizations (P < 0.001) were significantly reduced. The nonsurviving patients (n = 7/31, 22.6%) were significantly older (P = 0.02) and tended to have a larger cardiothoracic ratio (P = 0.084) compared with the survivors. An absence of concomitant beta-blocker therapy was significantly associated with a worse prognosis (oneyear mortality 2/21 versus 5/10, log rank, P = 0.011). Oral inotropic agents brought about improvements in the clinical parameters of CHF and a reduction in ER visits and hospitalizations. However, concomitant beta-blocker therapy should be considered for patients receiving oral inotropic treatment. |
| تدمد: | 1349-3299 1349-2365 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::33f18b9418dcf6ebfd1a636d626dd26aTest https://doi.org/10.1536/ihj.54.75Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........33f18b9418dcf6ebfd1a636d626dd26a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13493299 13492365 |
|---|